<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medical  Diagnosis</journal-title></journal-title-group><issn pub-type="epub">2164-540X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/MD.2019.92014</article-id><article-id pub-id-type="publisher-id">MD-30843</article-id><article-categories><subj-group subj-group-type="heading"><subject>MD20190200000_35308967.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  预测性生物标记物在急性移植物抗宿主病中的研究进展
  Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>艳军</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>易</surname><given-names>甜甜</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>学东</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>南方医科大学南方医院儿科，广东 广州</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><aff id="aff1"><addr-line>南方医科大学附属佛山妇幼保健院儿科，广东 佛山</addr-line></aff><pub-date pub-type="epub"><day>03</day><month>06</month><year>2019</year></pub-date><volume>09</volume><issue>02</issue><fpage>71</fpage><lpage>76</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  急性移植物抗宿主病是异基因造血干细胞移植后不可避免遇到的棘手问题，临床上主要依靠临床表现及病理活检进行诊断。预测性生物标记物成为近年来研究热点，多中心共同研究成为必然趋势，本文对近年来国内外预测性生物标记物的研究进行总结归纳，主要包括对基因、蛋白质及细胞水平的研究。 
   Acute graft-versus-host disease (aGVHD) is the primary source of morbidity and mortality after HSCT. Diagnosis of aGVHD is typically based on clinical symptoms and confirmed by biopsy. In this review, we aim to summarize some of the recent developments of biomarkers in the field of al-lo-HSCT, including miRNAs, Cellular biomarkers, Proteomic biomarkers and biomarker panels. At present, the research of biomarkers has become a hotspot. However, predictive biomarkers still require a coordinated multicenter approach with coordinated times of sampling and centralized analysis of biomarker levels.
 
</p></abstract><kwd-group><kwd>异基因造血干细胞移植，急性移植物抗宿主病，生物标记物, Allogeneic Hematopoietic Stem Cell Transplantation</kwd><kwd> Acute Graft-versus-Host Disease</kwd><kwd> Biomarkers</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>预测性生物标记物在急性移植物抗宿主病中的研究进展<sup> </sup></title><p>徐艳军<sup>1</sup>，易甜甜<sup>2</sup>，吴学东<sup>2</sup></p><p><sup>1</sup>南方医科大学附属佛山妇幼保健院儿科，广东 佛山</p><p><sup>2</sup>南方医科大学南方医院儿科，广东 广州</p><p><img src="//html.hanspub.org/file/8-2170214x1_hanspub.png" /></p><p>收稿日期：2019年5月29日；录用日期：2019年6月13日；发布日期：2019年6月20日</p><disp-formula id="hanspub.30843-formula53"><graphic xlink:href="//html.hanspub.org/file/8-2170214x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>急性移植物抗宿主病是异基因造血干细胞移植后不可避免遇到的棘手问题，临床上主要依靠临床表现及病理活检进行诊断。预测性生物标记物成为近年来研究热点，多中心共同研究成为必然趋势，本文对近年来国内外预测性生物标记物的研究进行总结归纳，主要包括对基因、蛋白质及细胞水平的研究。</p><p>关键词 :异基因造血干细胞移植，急性移植物抗宿主病，生物标记物</p><disp-formula id="hanspub.30843-formula54"><graphic xlink:href="//html.hanspub.org/file/8-2170214x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/8-2170214x7_hanspub.png" /> <img src="//html.hanspub.org/file/8-2170214x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation, allo-HSCT)是目前治疗血液系统恶性肿瘤最有效的方法之一。然而移植物抗宿主病成为移植后患者死亡的主要原因之一 [<xref ref-type="bibr" rid="hanspub.30843-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.30843-ref2">2</xref>] 。移植物抗宿主病(graft-versus-host disease, GVHD)根据发病时间、病程及临床表现分为急性移植物抗宿主病(aGVHD)和慢性移植物抗宿主病(cGVHD)两种，aGVHD主要引起皮肤、肝脏、肠道等损伤，其诊断主要依靠靶器官受损的临床表现及病理活检，一旦发生严重GVHD，往往造成难以恢复的器官损害，病死率高 [<xref ref-type="bibr" rid="hanspub.30843-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.30843-ref4">4</xref>] 。因此，寻找合适的aGVHD的生物标记物，预测aGVHD的发生并在严重临床症状发生前预防性治疗至关重要。</p><p>理想的生物标志物除了判定是否发生aGVHD以及鉴别cGVHD，还应该具有以下特点：1) 具体和敏感地反映疾病状态；2) 无创；3) 快速，简单，准确，便宜，标准化。因此，aGVHD生物标记物有助于疾病诊断、监测aGVHD的发生、发展以及判断预后及早期治疗。本文将从基因水平、蛋白质水平及细胞水平对目前发现的各种生物标记物逐一介绍。</p></sec><sec id="s4"><title>2. 基因水平生物标记物</title><p>miRNAs是一类长度约22个核苷酸的非编码RNA，它能够通过对靶基因mRNA的降解而减少或者阻止相应蛋白表达。目前血浆miRNA的分泌机制还不清楚，Xiao等 [<xref ref-type="bibr" rid="hanspub.30843-ref5">5</xref>] 的假说是miRNA在供者T细胞攻击宿主过程有潜在的作用或在应对破坏靶细胞有重要作用。许多学者对动物和人类miRNA在aGVHD发病中的作用进行了研究，并筛选出有前景的生物标记物和治疗靶点 [<xref ref-type="bibr" rid="hanspub.30843-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.30843-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.30843-ref8">8</xref>] 。国内胡彬、付伟等 [<xref ref-type="bibr" rid="hanspub.30843-ref9">9</xref>] 经过临床试验发现本：miR-423，miR199a-3p，miR-93，在aGVHD中表达增高，而miR-377表达无明显差异，与xiao等人的结果基本一致。但这些研究miRNAs缺乏特异性，导致需要同时使用多种miRNAs来增加这些生物标志物的特异性和诊断性能。</p></sec><sec id="s5"><title>3. 蛋白质水平生物标记物(见表1)</title><p>1) 系统性生物标记物</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Prediction of aGVHD protein level biomarker</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分类</th><th align="center" valign="middle" >种类</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >系统性生物标记物</td><td align="center" valign="middle" >内皮损伤标记物：血浆血管性血友病因子(vWF)、血清可溶性粘附分子、 血清VACM-1及CD62E水平、血管生成素2 (Ang-2)、趋化因子IL8 (CXCL8)、 内皮微粒(EPM)、循环内皮细胞(CECs)</td></tr><tr><td align="center" valign="middle" >细胞因子及其受体：IL-2R、ST2、TNFR1、IL-7、sBAFF</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >器官特异性生物标记物</td><td align="center" valign="middle" >下消化道生物标记物：REG3a，CK-18、S100、Tim-3</td></tr><tr><td align="center" valign="middle" >肝脏特异性生物标记物：肝细胞生长因子(HGF)</td></tr><tr><td align="center" valign="middle" >皮肤特异性生物标记物：弹力素(Elafin)</td></tr><tr><td align="center" valign="middle" >生物标记物组</td><td align="center" valign="middle" >1) TIM3, IL-6, sTNFR1, ST2 2) IL-2Ra, TNFR1, HGF, IL-8, elafin, REG3a 3) TNFR1, ST2, REG3a 4) CD4 + Tcell, CD8 + Tcell, CD19 - CD21 + precursor B cells, CD4/CD8 Tcell ratio, IL-2R</td></tr></tbody></table></table-wrap><p>表1. 预测 aGVHD蛋白质水平生物标记物</p><p>a) 内皮损伤标记物</p><p>移植前预处理是内皮早期损伤的重要因素，Filipovich AH等 [<xref ref-type="bibr" rid="hanspub.30843-ref10">10</xref>] 实验发现移植前预处理，无论是化疗或是照射，均对内皮细胞有不同程度损伤，且损伤程度与预处理强度相关。由于检测方法等限制，到目前为止，尚无有效的、非侵袭性的生物学标记应用于GVHD的诊疗中。</p><p>b) 血清可溶性IL-2受体(IL-2R)</p><p>炎症因子在T细胞激活的过程中发挥重要作用，活化的T细胞表达IL-2受体。研究表明血清可溶性IL-2R水平是aGVHD中非常有用的生物标志物，连续检测Allo-HSCT后IL-2L水平，发现它自移植后开始升高，2~4周后达峰，而且aGVHD患者血清其峰值显著高于无aGVHD患者，并与aGVHD严重程度相关 [<xref ref-type="bibr" rid="hanspub.30843-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.30843-ref12">12</xref>] ，结果显示sIL-2R指数 ≥ 4.5 [风险比(HR) 3.5，P &lt; 0.01]，是II~IV级急性GVHD的重要危险因素。虽然回顾性研究表明IL-2水平能够预测aGVHD的发生，但仍需要更多的前瞻性研究来证明。</p><p>c) ST2</p><p>ST2是Toll样/IL-1受体(IL-R)超家族成员之一，可溶型ST2可以作为IL-33的诱骗性受体，使Th2细胞向Th1细胞漂移，可能在aGVHD的病理生理学过程中发挥重要作用。Nelson等对非清髓性异基因造血干细胞移植患者的研究显示，移植后7+、+14、+21血清浆ST2水平与aGVHD的发生风险呈正相关 [<xref ref-type="bibr" rid="hanspub.30843-ref13">13</xref>] 。唐伦、颜红菊等人经临床研究发现allo-HSCT后+7、+56 d发生aGVHD患者的血清ST2含量较未发生aGVHD患者明显升高(P &lt; 0.05) [<xref ref-type="bibr" rid="hanspub.30843-ref14">14</xref>] 。不同强度预处理下，ST2浓度变化较大，每种预处理下需要各自的阈值来确定。此外，这些研究中ST2的测量时间是不统一的，需要前瞻性地连续检测ST2，提高生物标志物的预测价值。</p><p>2) 器官特异性生物标记物</p><p>a) 下消化道生物标记物</p><p>下消化道GVHD (LGI GVHD)在移植后发病率高达60%。LGI aGVHD的临床症状通常很严重，包括通过大量的分泌性腹泻，腹部痉挛性疼痛、腹胀、麻痹性肠梗阻、肠道出血等。因此，利用生物标志物来预测或评估LGI GVHD程度非常重要。目前研究最广泛生物标志物包括：REG3a，CK-18，S100和Tim-3。</p><p>b) 肝脏特异性生物标记物</p><p>肝细胞生长因子(Hepatocyte growth factor, HGF)的靶细胞为上皮细胞及内皮细胞，包括肝细胞。据报道，血清HGF在肝病、慢性肾衰竭、全身炎症反应综合征以及白血病、乳腺癌、胃癌等恶性疾病中有升高。Okamoto等 [<xref ref-type="bibr" rid="hanspub.30843-ref15">15</xref>] 检测了38例接受allo-HSCT患者的HGF水平变化，发现aGVHD患者血清HGF水平明显高于aGVHD患者，且与aGVHD的严重程度成正相关，提示HGF对aGVHD的诊断及预后判断具有重要意义。现已证明包括肝细胞生长因子在内的生物标记物组能够预测移植后1年NRM和长期生存情况，不论GVHD的严重程度。并且HGF是生物标记物组中最主要的预测因素 [<xref ref-type="bibr" rid="hanspub.30843-ref16">16</xref>] 。</p><p>c) 皮肤特异性生物标记物</p><p>弹力素(Elafin)是一种主要表达于上皮细胞的弹性特异性蛋白酶抑制剂。体内研究表明aGVHD患者体内的炎性细胞因子能够刺激上皮细胞表达Elafin [<xref ref-type="bibr" rid="hanspub.30843-ref17">17</xref>] 。Elafin作为皮肤aGVHD的生物标记物相较其他aGVHD生物标记物而言，Elafin是鉴别皮肤GVHD与其他出疹性疾病(药物疹，植入综合征、皮肤白血病、病毒或真菌疹最佳的单标记物。elafin与各级GVHD的发生及1年非复发死亡率(Non-relapse mortality, NRM)相关，具有良好的预测价值 [<xref ref-type="bibr" rid="hanspub.30843-ref18">18</xref>] 。</p><p>3) 生物标记物组</p><p>单一的生物标记物在预测aGVHD发生发面往往缺乏特异性，目前已有许多学者对生物标记物组进行研究。生物标记物组提供了aGVHD预后及预测信息，包括最大严重程度，对治疗的反应和死亡率。如TIM3，IL-6，sTNFR1，ST2的血浆水平在预测更严重的GVHD和NRM方面具有重要意义 [<xref ref-type="bibr" rid="hanspub.30843-ref19">19</xref>] 。Levine及Ferrara等人最近完成了依赖于三种生物标志物(Reg3 alpha, ST2和sTNFR1)的aGvHD安娜堡评分(Ann Arbor Score)这一目标。如果GvHD发病时评分很高，则可预测移植后28天的治疗反应和6个月的NRM。这是第一个可用于指导风险调整治疗的生物标记物评分 [<xref ref-type="bibr" rid="hanspub.30843-ref20">20</xref>] 。Holger Budde等 [<xref ref-type="bibr" rid="hanspub.30843-ref21">21</xref>] 人测试了28例移植后患者血液中生物标记物的含量，研究发现，当使用五项参数的生物标记物组(CD4 + Tcell, CD8 + Tcell, CD19~CD21 + 前Bcell, CD4/CD8 Tcell比率，IL-2R)预测aGVHD发生时能得到最大曲线下面积。与此同时，他们还发现移植后CD8 + T细胞占全部单核细胞2.3%以上能够预测至少12月的无复发生存率(Relapse-free Survival, RFS)，从而成为预测RFS的一项生物标记物。</p></sec><sec id="s6"><title>4. 细胞水平生物标记物</title><p>造血干细胞移植后患者造血功能一般在移植后15天左右恢复，而免疫功能重建则需要较长时间。临床上对移植后患者免疫功能的监测主要为T细胞亚群及Treg的监测。常规T细胞亚群监测主要根据CD4+/CD8+来评估免疫状态，SchwingerW等人发现，常规T细胞亚群监测对Allo-HSCT术后免疫状态评估无益 [<xref ref-type="bibr" rid="hanspub.30843-ref22">22</xref>] 。由于CD4 + T的生成和成熟主要依赖胸腺，而CD8 + T则不完全依赖胸腺，故CD4+/CD8+可持续倒置超过1年，因此常规T细胞亚群监测只能反映T细胞构成比的变化，而不能准确反映术后免疫状态。</p><p>CD4 + CD25 + Treg细胞是一类具有免疫无能及免疫抑制功能的T细胞。FoxP3特异性表达于CD4 + CD25 + Treg细胞的胞质中，为Treg的分化、发育其重要作用，并维持其免疫抑制功能。Magenau等人已证实CD4 + CD25 + FOXP3 + Treg可作为预测aGVHD的发生及判断预后的生物标记物 [<xref ref-type="bibr" rid="hanspub.30843-ref21">21</xref>] 。Xingli Zou等人研究发现脐带血CD4 + ATs中的FoxP3 + Treg细胞可能有助于减轻CBT后观察到的aGVHD的严重程度 [<xref ref-type="bibr" rid="hanspub.30843-ref23">23</xref>] 。换言之，Treg细胞水平的监测对移植后免疫状态具有重要价值，通过监测Treg水平亦可及时发现过度免疫抑制状态，调整免疫抑制剂的使用，减少术后不良反应。</p></sec><sec id="s7"><title>5. 总结</title><p>总之，目前临床上aGVHD的预测性生物标记物缺乏，预测aGVHD并指导预防性治疗是众多移植患者的福音。目前对于aGVHD的生物标记物研究大多局限于动物实验及小样本临床研究，由于患者异质性、测量时间及手段差异、预处理强度不同、GVHD的预防策略不同等因素，不同临床研究中心之间还存在不一致的结果。以及联合生物标记物组、生物标记物评分、临床特征及危险因素(移植前CRP，IL-31和移植早期液体保留是异基因移植后移植相关死亡率(Transplant related mortality, TRM)及生存率的独立危险因素 [<xref ref-type="bibr" rid="hanspub.30843-ref24">24</xref>] )是否提高整体预测能力，还需要更多大型多中心前瞻性研究继续验证。</p></sec><sec id="s8"><title>基金项目</title><p>广东省科技计划项目2014A020212186，广州市科技计划项目201607010241。</p></sec><sec id="s9"><title>文章引用</title><p>徐艳军,易甜甜,吴学东. 预测性生物标记物在急性移植物抗宿主病中的研究进展Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation[J]. 医学诊断, 2019, 09(02): 71-76. https://doi.org/10.12677/MD.2019.92014</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.30843-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Nassereddine, S., Rafei, H., Elbahesh, E. and Tabbara, I. (2017) Acute Graft versus Host Disease: A Comprehensive Review. Anti-cancer Research, 37, 1547-1555.&lt;br&gt; https://doi.org/10.21873/anticanres.11483</mixed-citation></ref><ref id="hanspub.30843-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Flinn, A.M. and Gennerya, R. (2017) Treatment of Pediatric Acute Graft-versus-Host Disease-Lessons from Primary Immunodeficiency. Frontiers in Immunology, 8, 328. &lt;br&gt; https://doi.org/10.3389/fimmu.2017.00328</mixed-citation></ref><ref id="hanspub.30843-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J.-Z., Zhang, J.-Q. and Sun, L.-X. (2016) Mechanisms for T Cell Tolerance Induced with Granulocyte Colony-Stimulating Factor. Molecular Immunology, 70, 56-62. &lt;br&gt;https://doi.org/10.1016/j.molimm.2015.12.006</mixed-citation></ref><ref id="hanspub.30843-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">王越. 调节性B细胞的免疫调控机制及其在移植物抗宿主病中的作用[J]. 海南医学, 2019, 30(6): 787-791.</mixed-citation></ref><ref id="hanspub.30843-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Xiao, B., Wang, Y., Li, W., et al. (2013) Plasma microRNA Signature as a Noninvasive Biomarker for Acute Graft-versus-Host Disease. Blood, 122, 3365-3375. &lt;br&gt;https://doi.org/10.1182/blood-2013-06-510586</mixed-citation></ref><ref id="hanspub.30843-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Xie, L.N., Zhou, F., Liu, X.M., Fang, Y., Yu, Z., et al. (2014) Serum microRNA155 Is Increased in Patients with Acute Graft-versus-Host Disease. Clinical Transplantation, 28, 314-323. &lt;br&gt;https://doi.org/10.1111/ctr.12314</mixed-citation></ref><ref id="hanspub.30843-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ranganathan, P., Heaphy, C.E., Costinean, S., Stauffer, N., Na, C., et al. (2012) Regulation of Acute Graft-versus-Host Disease by microRNA-155. Blood, 119, 4786-4797. &lt;br&gt;https://doi.org/10.1182/blood-2011-10-387522</mixed-citation></ref><ref id="hanspub.30843-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Zhao, X., Ye, X., Luo, H.X., Zhao, T.F., et al. (2015) Plasma microRNA-586 Is a New Biomarker for Acute Graft-versus-Host Disease. Annals of Hematology, 94, 1505-1514. &lt;br&gt;https://doi.org/10.1007/s00277-015-2414-z</mixed-citation></ref><ref id="hanspub.30843-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">胡彬, 付伟, 等. 异基因造血干细胞移植后血浆microRNA的表达与急性移植物抗宿主病的相关性研究[J]. 中国实验血液学杂志, 2016, 24(3): 827-832.</mixed-citation></ref><ref id="hanspub.30843-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zeng, L., Yan, Z., Ding, S., Xu, K. and Wang, L. (2008) Endothelial Injury, an Intriguing Effect of Methotrexate and Cyclophosphamide during Hematopoietic Stem Cell Transplantation in Mice. Transplantation Proceedings, 40, 2670-2673. &lt;br&gt; https://doi.org/10.1016/j.transproceed.2008.06.038</mixed-citation></ref><ref id="hanspub.30843-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Almici, C., Skert, C., Verardi, R., et al. (2014) Changes in Circulating En-dothelial Cells Count Could Become a Valuable Tool in the Diagnostic Definition of Acute Graft-versus-Host Disease. Transplantation, 98, 706-712.  
https://doi.org/10.1097/TP.0000000000000385</mixed-citation></ref><ref id="hanspub.30843-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Nakamura, Y., Tanaka, Y., Sugiyama, A., Yamamoto, K., et al. (2016) Soluble Interleukin-2 Receptor Index Predicts the Development of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors. International Journal of Hematology, 103, 436-443. &lt;br&gt;https://doi.org/10.1007/s12185-016-1936-z</mixed-citation></ref><ref id="hanspub.30843-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Nelson, R.P., Khawaja, M.R., Perkins, S.M., Elmore, L., et al. (2014) Prognos-tic Biomarkers for Acute Graft-versus-Host Disease Risk after Cyclophosphamide-Fludarabine Nonmyeloablative Allotransplantation. Biology of Blood and Marrow Transplantation, 20, 1861-1864. &lt;br&gt; https://doi.org/10.1016/j.bbmt.2014.06.039</mixed-citation></ref><ref id="hanspub.30843-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">唐伦, 颜红菊, 等. 异基因造血干细胞移植患者血清生物标志物水平变化与aGVHD的关系[J]. 中国输血杂志, 2016, 29(6): 598-601.</mixed-citation></ref><ref id="hanspub.30843-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Okamoto, T., Takatsuka, H., Fujimori, Y., Wada, H., Iwasaki, T. and Kakishita, E. (2001) Increased Hepatocyte Growth Factor in Serum in Acute Graft-versus-Host Disease. Bone Marrow Transplant, 28, 197-200.  
https://doi.org/10.1038/sj.bmt.1703095</mixed-citation></ref><ref id="hanspub.30843-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Paczesny, S., Krijanovski, O.I., Braun, T.M., et al. (2009) A Biomarker Panel for Acute Graft-versus-Host Disease. Blood, 113, 273-278.</mixed-citation></ref><ref id="hanspub.30843-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Pfundt, R., Wingens, M., Bergers, M., Zweers, M., Frenken, M. and Schalk-wijk, J. (2000) TNF-alpha and Serum Induce SKALP/elafin Gene Expression in Human Keratinocytes by a p38 MAP Ki-nase-Dependent Pathway. Archives of Dermatological Research, 292, 180-187. &lt;br&gt;https://doi.org/10.1007/s004030050475</mixed-citation></ref><ref id="hanspub.30843-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Paczesny, S., Braun, T.M., Levine, J.E., et al. (2010) Elafin Is a Biomarker of Graft-versus-Host Disease of the Skin. Science Translational Medicine, 2, 13ra2. &lt;br&gt;https://doi.org/10.1126/scitranslmed.3000406</mixed-citation></ref><ref id="hanspub.30843-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">McDonald, G.B., Tabellini, L., Storer, B.E., Lawler, R.L., Martin, P.J. and Hansen, J.A. (2015) Plasma Biomarkers of Acute GVHD and Nonrelapse Mortality: Predictive Value of Measurements before GVHD Onset and Treatment. Blood, 126, 113-120. &lt;br&gt;https://doi.org/10.1182/blood-2015-03-636753</mixed-citation></ref><ref id="hanspub.30843-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Levine, J.E., Braun, T.M., Harris, A.C., et al. (2015) A Prognostic Score for Acute Graft-versus-Host Disease Based on Biomarkers: A Multicenter Study. The Lancet Haematology, 2, e21-e29.  
https://doi.org/10.1016/S2352-3026(14)00035-0</mixed-citation></ref><ref id="hanspub.30843-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Budde, H., Papert, S., Maas, J.-H., Reichardt, H.M., Wulf, G., et al. (2017) Prediction of Graft-versus-Host Disease: A Biomarker Panel Based on Lymphocytes and Cytokines. Annals of Hematology, 96, 1127-1133.</mixed-citation></ref><ref id="hanspub.30843-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Schwinger, W., Weber-Mzell, D., Zois, B., et al. (2006) Immune Reconstitution after Purified Autologous and Al-logeneic Blood Stem Cell Transplantation Compared with Unmanipulated Bone Marrow Transplantation in Children. British Journal of Haematology, 135, 76-84. &lt;br&gt; https://doi.org/10.1111/j.1365-2141.2006.06244.x</mixed-citation></ref><ref id="hanspub.30843-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Zou, X., Lin, X., et al. (2016) Donor-Derived Regulatory T Cells Attenuate the Severity of Acute Graft-versus-Host Disease after Cord Blood Transplantation. The Tohoku Journal of Experimental Medicine, 239, 193-202.</mixed-citation></ref><ref id="hanspub.30843-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Tvedt, T.H., Lie, S.A., et al. (2016) Pre-Transplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation. International Journal of Molecular Sciences, 17, 1823.  
https://doi.org/10.3390/ijms17111823</mixed-citation></ref></ref-list></back></article>